simufilam
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started May 4, 2021 (NCT04932655)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCC2(CC1)NCC(=O)N2Cc1ccccc1- Mol. weight
- 259.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650230 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06390410 | Phase 1 | Jun 26, 2024 | Cassava Sciences |
| NCT06195319 | Phase 1 | Feb 7, 2024 | Cassava Sciences |
| NCT05575076 | Phase 3 | Nov 7, 2022 | Cassava Sciences |
| NCT05352763 | Phase 2 | May 12, 2022 | Cassava Sciences |
| NCT05026177 | Phase 3 | Nov 30, 2021 | Cassava Sciences, Premier Research Group |
| NCT04994483 | Phase 3 | Nov 30, 2021 | Cassava Sciences, Premier Research Group |
| NCT04932655 | Phase 1 | May 4, 2021 | Cassava Sciences, Worldwide Clinical Trials |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cassava Sciences | For profit | 7 | 7 | 3 | 2021 |
| Premier Research Group | For profit | 2 | 0 | 1 | 2021 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1